News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Enzymotec Announces Signing Of Final Settlement And License Agreement With Neptune Technologies & Bioressources Inc.



4/28/2014 9:14:25 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MIGDAL HA'EMEQ, Israel, April 28, 2014 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that it signed a final settlement and license agreement with Neptune Technologies & Bioressources Inc. (Nasdaq:NEPT) ("Neptune") and Acasti Pharma Inc. ("Acasti"). The International Trade Commission's ("ITC") investigation and related U.S. federal court actions will be terminated and dismissed accordingly.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES